OncoMatch/Clinical Trials/NCT05805098
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Is NCT05805098 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Venetoclax and Homoharringtonine for acute myeloid leukemia.
Treatment: Venetoclax · Homoharringtonine · Cytarabine — This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
White blood cell (WBC) count < 25 × 10^9 /L (hydroxyurea is permitted to meet this criterion)
Kidney function
Creatinine clearance ≥ 45 mL/min calculated by the Cockcroft Gault formula or measured by 24-hour urine collection; Creatinine clearance < 45 mL/min [excluded]
Liver function
Serum aspartate aminotransferase (AST) ≤ 3.0 × ULN, Serum alanine aminotransferase (ALT) ≤ 3.0 × ULN (unless considered due to leukemic organ involvement), Total bilirubin ≤ 1.5 × ULN, Moderate hepatic impairment with total bilirubin > 1.5 × ULN [excluded]
Cardiac function
Cardiac history of congestive heart failure requiring treatment or ejection fraction ≤ 50% or chronic stable angina [excluded]
Cardiac history of congestive heart failure requiring treatment or ejection fraction ≤ 50% or chronic stable angina. Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume during the first second (FEV1) ≤ 65%. Creatinine clearance < 45 mL/min. Moderate hepatic impairment with total bilirubin > 1.5 × ULN. Laboratory values: Creatinine clearance ≥ 45 mL/min, AST ≤ 3.0 × ULN, ALT ≤ 3.0 × ULN (unless considered due to leukemic organ involvement), Total bilirubin ≤ 1.5 × ULN, WBC count < 25 × 10^9 /L (hydroxyurea is permitted to meet this criterion)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05805098 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages